Physician profile
Mohamed Hasham
NPI 1982985594
$2,108.87
in general payments reported to CMS, 2019-2025
14 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $83.08 · 2021: $15.20 · 2022: $370 · 2023: $604 · 2024: $441 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $540.49 | 2019-2025 | Veklury |
| Viiv Healthcare Company | $513.06 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Abbvie INC. | $217.57 | 2020-2024 | |
| Insmed, INC. | $202.78 | 2022-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $116.58 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Melinta Therapeutics, LLC | $108.20 | 2019-2025 | Kimyrsa, Orbactiv, Vabomere |
| Aimmune Therapeutics, INC. | $102.91 | 2024-2025 | Vowst |
| Shionogi INC | $101.45 | 2024-2025 | Fetroja |
| Theratechnologies INC. | $68.25 | 2023 | Egrifta, Trogarzo |
| Janssen Products, LP | $54.99 | 2022 | |
| Janssen Biotech, INC. | $33.55 | 2022-2023 | Symtuza |
| Pfizer INC. | $17.34 | 2025 | |
| La Jolla Pharmaceutical Company | $16.70 | 2025 | Xacduro |
| Allergan, INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Hasham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.